These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 39373900)

  • 1. Pre-treatment [18F]FDG PET/CT biomarkers for the prediction of antibody-drug conjugates efficacy in metastatic breast cancer.
    Seban RD; Champion L; De Moura A; Lerebours F; Loirat D; Pierga JY; Djerroudi L; Genevee T; Huchet V; Jehanno N; Bidard FC; Buvat I
    Eur J Nucl Med Mol Imaging; 2024 Oct; ():. PubMed ID: 39373900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of Pretreatment 18F-FDG-PET/CT Parameters on the Outcome of First-Line Therapy in Patients with Metastatic Breast Cancer.
    Li Y; Liu C; Wang B; Hu X; Gong C; Zhao Y; Xie Y; Zhang Y; Song S; Yang Z; Wang B
    Int J Gen Med; 2021; 14():1797-1809. PubMed ID: 34007206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Antibody-Drug-Conjugates in Routine Clinical Practice for the Treatment of Metastatic Breast Cancer: Adherence, Efficacy and Tolerability - Real-World Data from German Breast Centers.
    Schäffler H; Jakob D; Huesmann S; Pfister K; Veselinovic K; Schochter F; Leinert E; Fink V; Rack B; Englisch A; Volmer LL; Engler T; Frevert ML; Juhasz-Böss I; Brucker S; Heublein S; Janni W; Taran FA; Hartkopf A; Dannehl D
    Geburtshilfe Frauenheilkd; 2024 Sep; 84(9):855-865. PubMed ID: 39229630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of sacituzumab govitecan and trastuzumab deruxtecan on stable and active brain metastases in metastatic breast cancer patients-a multicenter real-world analysis.
    Dannehl D; Jakob D; Mergel F; Estler A; Engler T; Volmer L; Frevert ML; Matovina S; Englisch A; Tegeler CM; Rohner A; Seller A; Hahn M; Pfister K; Fink A; Popp I; Lorenz S; Tabatabai G; Juhasz-Böss I; Janni W; Brucker S; Taran FA; Hartkopf A; Schäffler H
    ESMO Open; 2024 May; 9(5):102995. PubMed ID: 38636292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape.
    Adams E; Wildiers H; Neven P; Punie K
    ESMO Open; 2021 Aug; 6(4):100204. PubMed ID: 34225076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of metabolic tumour volume on baseline
    Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of
    Geng H; Lian K; Zhang W
    Quant Imaging Med Surg; 2024 Jan; 14(1):325-334. PubMed ID: 38223089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [
    Xu HQ; Song LJ; Ding CY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1690-1700. PubMed ID: 38071047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Clinical Outcomes With Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
    Alaklabi S; Roy AM; Zagami P; Chakraborty A; Held N; Elijah J; George A; Attwood K; Shaikh SS; Chaudhary LN; Abdou Y; Gandhi S
    JCO Oncol Pract; 2024 Oct; ():OP2400242. PubMed ID: 39353151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment
    Gong C; Ma G; Hu X; Zhang Y; Wang Z; Zhang J; Zhao Y; Li Y; Xie Y; Yang Z; Wang B
    Oncologist; 2018 Oct; 23(10):1144-1152. PubMed ID: 30082489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of 18F-FDG lesion dissemination features in patients with peripheral T-cell lymphoma (PTCL).
    Xie Y; Teng Y; Jiang C; Ding C; Zhou Z
    Jpn J Radiol; 2023 Jul; 41(7):777-786. PubMed ID: 36752954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT Predict Outcomes in T-Cell Lymphoblastic Lymphoma.
    Feng X; Wen X; Li L; Sun Z; Li X; Zhang L; Wu J; Fu X; Wang X; Yu H; Ma X; Zhang X; Xie X; Han X; Zhang M
    Cancer Res Treat; 2021 Jul; 53(3):837-846. PubMed ID: 33285054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics.
    Seban RD; Nemer JS; Marabelle A; Yeh R; Deutsch E; Ammari S; Moya-Plana A; Mokrane FZ; Gartrell RD; Finkel G; Barker L; Bigorgne AE; Schwartz LH; Saenger Y; Robert C; Dercle L
    Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2298-2310. PubMed ID: 31346755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer.
    Poumeaud F; Morisseau M; Cabel L; Gonçalves A; Rivier C; Trédan O; Volant E; Frenel JS; Ladoire S; Jacot W; Jamelot M; Foka Tichoue H; Patsouris A; Teixeira L; Bidard FC; Loirat D; Brunet M; Levy C; Bailleux C; Cabarrou B; Deleuze A; Uwer L; Deluche E; Grellety T; Franchet C; Fiteni F; Bischoff H; Vion R; Pagliuca M; Verret B; Bécourt S; Reverdy T; de Nonneville A; Dalenc F
    Br J Cancer; 2024 Sep; 131(4):702-708. PubMed ID: 38918555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors.
    Seban RD; Mezquita L; Berenbaum A; Dercle L; Botticella A; Le Pechoux C; Caramella C; Deutsch E; Grimaldi S; Adam J; Ammari S; Planchard D; Leboulleux S; Besse B
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1147-1157. PubMed ID: 31754795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual Tracers of 16α-[18F]fluoro-17β-Estradiol and [18F]fluorodeoxyglucose for Prediction of Progression-Free Survival After Fulvestrant Therapy in Patients With HR+/HER2- Metastatic Breast Cancer.
    Liu C; Xu X; Yuan H; Zhang Y; Zhang Y; Song S; Yang Z
    Front Oncol; 2020; 10():580277. PubMed ID: 33251143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4.
    Seban RD; Moya-Plana A; Antonios L; Yeh R; Marabelle A; Deutsch E; Schwartz LH; Gómez RGH; Saenger Y; Robert C; Ammari S; Dercle L
    Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2301-2312. PubMed ID: 32206839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Total metabolic tumor volume on
    Tricarico P; Chardin D; Martin N; Contu S; Hugonnet F; Otto J; Humbert O
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38649279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Values of Baseline
    Zhou Y; Zhang X; Qin H; Zhao Z; Li J; Zhang B; Sang S; Wu Y; Deng S
    Biomed Res Int; 2020; 2020():9746716. PubMed ID: 32185229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal Sequential Strategies for Antibody-Drug Conjugate in Metastatic Breast Cancer: Evaluating Efficacy and Cross-Resistance.
    Chen M; Huang R; Chen R; Pan F; Shen X; Li H; Rong Q; An X; Xue C; Shi Y
    Oncologist; 2024 Aug; 29(8):e957-e966. PubMed ID: 38574190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.